NON-ALCOHOLIC STEATOHEPATITIS (NASH) THERAPEUTICS AND DIAGNOSTICS MARKET ANALYSIS

Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics MarketSize and Trends

The global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market was valued at US$ 14,624.2 Mn in 2022 and is forecast to reach a value of US$ 63,354.6 Mn by 2030 at a CAGR of 20.13% between 2023 and 2030. The global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market is experiencing strong growth due to the rise in NASH-affected population and rise in diabetic and obese population across the globe. Moreover, increase in demand for safe and effective NASH therapeutics and diagnostics and initiatives by government/non-government organizations is expected to boost growth of the market. However, factors such as lack of effective diagnostics for NAFLD and slow advancements in the therapeutic field and are expected to hamper the growth of the market.

With the increase in the prevalence of NASH, the demand for novel therapeutics and diagnostics is also increasing at a rapid pace. NASH is diagnosed when microscopic examination of the tissue shows inflammation and damage to the liver cells along with fat. Players in the market are focusing on developing novel diagnostic tests, which can directly target the developed markets and benefit both, patients, and the firm. This trend is expected to continue over the forecast period, driving the growth of the NASH therapeutics and diagnostics market.

There are an increasing number of awareness programs for the disease to help patients, healthcare professionals, and researchers better diagnose/treat NASH. For instance, International NASH Day is an initiative started by the Global Liver Institute to raise awareness of the growing worldwide epidemic of non-alcoholic fatty liver disease (NAFLD) and its more advanced form, non-alcoholic steatohepatitis (NASH). This trend is also expected to continue during the forecast period, driving the growth of the NASH therapeutics and diagnostics market.